Plain-English translation of NCT05170126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This is a safety registry that follows pregnant women with multiple sclerosis who are taking or have taken ozanimod, a medication used to treat the condition. Researchers want to understand how this medication affects pregnancy outcomes and infant health so that you and your doctor can make the best treatment decisions together.
When you have multiple sclerosis and become pregnant, deciding whether to continue your medication is challenging—you want to manage your disease while protecting your baby. This study exists to gather real-world information about how this medication affects pregnancies, so there's better evidence to guide these important decisions.
You likely qualify if…
You likely don't qualify if…
You would share information about your pregnancy, health history, and how the medication or other treatments you took during pregnancy affected you and your baby. This is an observational study, meaning researchers follow your medical journey rather than assigning you to a specific treatment—they're simply collecting data from women in different groups (those taking the medication, those on other MS treatments, and those not on MS medications during pregnancy). You'll likely have periodic check-ins where you share updates about your pregnancy and your baby's health.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Germany
Sponsor
Bristol-Myers Squibb
Enrollment target
~1,182 participants
Started
July 2022
Primary completion
June 2032
Sex
Female only
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Study Connect Contact Center www.BMSStudyConnect.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.